TPO and autoimmune thrombocytopenic purpura: Nevertheless, there were noticeable drawbacks to using TPO-RAs, such as a high rate of treatment-related adverse events, especially thrombotic events, which affected almost one-third of patients and were far more common than those seen in primary ITP populations.